Advertisement
Advertisement
APLS
Apellis Pharmaceuticals, Inc. Common Stock
22.82
USDSponsored
+0.24
+1.05%
Feb 02, 15:59 UTC -5
Closed
After-Market
22.77
-0.05
-0.21%
APLS Earnings Reports
Positive Surprise Ratio
APLS beat 10 of 33 last estimates.
30%
Next Report
Date of Next Report
Feb 26, 2026
Estimate for Q4 25 (Revenue/ EPS)
$203.21M
/-$0.39
Implied change from Q3 25 (Revenue/ EPS)
-55.69%
/-123.35%
Implied change from Q4 24 (Revenue/ EPS)
-4.39%
/+39.29%
Apellis Pharmaceuticals, Inc. Common Stock earnings per share and revenue
On Oct 30, 2025, APLS reported earnings of 1.67 USD per share (EPS) for Q3 25, beating the estimate of 1.20 USD, resulting in a 38.11% surprise. Revenue reached 458.58 million, compared to an expected 414.81 million, with a 10.55% difference. The market reacted with a -31.02% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 21 analysts forecast an EPS of -0.39 USD, with revenue projected to reach 203.21 million USD, implying an decrease of -123.35% EPS, and decrease of -55.69% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Twist Bioscience Corporation Common Stock
Report Date
Feb 02, 2026 For Q1 26
Estimate
-$0.43
Actual
-$0.50
Surprise
-14.00%
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
FAQ
What were Apellis Pharmaceuticals, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Apellis Pharmaceuticals, Inc. Common Stock reported EPS of $1.67, beating estimates by 38.11%, and revenue of $458.58M, 10.55% above expectations.
How did the market react to Apellis Pharmaceuticals, Inc. Common Stock's Q3 2025 earnings?
The stock price moved down -31.02%, changed from $30.05 before the earnings release to $20.73 the day after.
When is Apellis Pharmaceuticals, Inc. Common Stock expected to report next?
The next earning report is scheduled for Feb 26, 2026.
What are the forecasts for Apellis Pharmaceuticals, Inc. Common Stock's next earnings report?
Based on 21
analysts, Apellis Pharmaceuticals, Inc. Common Stock is expected to report EPS of -$0.39 and revenue of $203.21M for Q4 2025.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement